טוען...
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
A novel therapeutic approach in cancer, attempting to stimulate host anti-tumor immunity, involves blocking of immune checkpoints. Lymphocyte activation gene 3 (LAG3) is an immune checkpoint receptor expressed on activated/exhausted T cells. When engaged by the major histocompatibility complex (MHC)...
שמור ב:
| הוצא לאור ב: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5477606/ https://ncbi.nlm.nih.gov/pubmed/28154084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.148965 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|